Early access to medicines scheme (EAMS) scientific opinion: Risdiplam in the treatment of type 1 and type 2 spinal muscular atrophy (SMA) in patients 2 months of age and older

Opinion issued for risdiplam in the treatment of patients 2 months of age and older with type 1 and type 2 SMA who are not suitable for authorised treatments, comprising public assessment report, treatment protocols & background information for NHS Medical Directors.

Medicines and Healthcare products Regulatory Agency